文献速递白血病

基于纳米抗体的天然筛选CD7靶向CAR-T细胞治疗急性髓系白血病

Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia.
PubMed 文献 · Blood · 2025-01-01

约30%的急性髓系白血病(AML)患者原始细胞表达CD7。这项1期临床试验评估了基于纳米抗体的dVHH NS7CAR-T细胞治疗CD7阳性复发/难治性AML的疗效与安全性,10例患者接受两个剂量水平(5×10^5/kg和1×10^6/kg)治疗,70%达到完全缓解,安全性可控,作者认为值得进一步研究。

要点

  • 10例CD7阳性复发/难治性AML患者接受dVHH NS7CAR-T治疗,7例(70%)达到完全缓解。
  • 80%患者发生轻度细胞因子释放综合征,无神经毒性发生。
  • 所有无应答和复发患者均出现CD7丢失。

核心结论

  • dVHH NS7CAR-T细胞治疗CD7阳性AML可能提供临床获益且安全性可控,值得进一步研究。

研究设计与样本

  • 1期临床试验,纳入10例CD7阳性复发/难治性AML患者,接受两个剂量水平(5×10^5/kg和1×10^6/kg)的dVHH NS7CAR-T细胞治疗。
  • 入组前患者接受过中位8线(范围3-17)既往治疗,7例曾接受过移植。
  • 试验注册号NCT04938115。

主要发现

  • 10例患者中7例(70%)在NS7CAR-T输注后达到完全缓解。
  • 中位观察时间178天(范围28-776)。
  • 7例达到完全缓解的患者中,3例既往移植后复发者接受了第二次异基因造血干细胞移植(allo-HSCT),其中1例在第401天无白血病生存,另2例分别在第241天和第776天死于非复发相关原因。
  • 3例未接受巩固性allo-HSCT的完全缓解患者在90天内复发。
  • 所有无应答者和复发患者均出现CD7丢失。

局限性

  • 作者在结论中写明本试验值得进一步研究(warranting further investigation)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 30% of patients with acute myeloid leukemia (AML) express CD7 on their myeloblasts. We have previously demonstrated that single-chain variable fragment (scFv)-based "naturally selected" CD7 chimeric antigen receptor T-cell (NS7CAR-T) therapy shows significant efficacy, with a favorable safety profile in T-cell lymphoid malignancies. Here, we derived dual variable heavy-chain domain of a heavy-chain antibody (dVHH) NS7CAR-Ts that have superior CD7 binding specificity, affinity to their scFv-based counterparts, and improved proliferative capability. In this phase 1 clinical trial, we evaluated the efficacy and safety of nanobody-based dVHH NS7CAR-Ts for patients with CD7+ refractory/relapsed AML. A cohort of 10 patients received dVHH NS7CAR-Ts across 2 dosage levels of 5 × 105/kg and 1 × 106/kg. Before enrollment, patients had undergone a median of 8 (range, 3-17) prior lines of therapy. Seven patients had prior transplants. After NS7CAR-T infusion, 7 of 10 (70%) patients achieved complete remission (CR). The median observation time was 178 days (range, 28-776). Among 7 patients who achieved CR, 3 who relapsed from prior transplants underwent a second allogeneic hematopoietic stem cell transplant (allo-HSCT). One patient remained leukemia free on day 401, and the other 2 died on day 241 and day 776, respectively, from nonrelapse-related causes. Three CR patients without consolidative (allo-HSCT) relapsed within 90 days. All the nonresponders and relapsed patients had CD7 loss. The treatment was well tolerated, with 80% experiencing mild cytokine release syndrome and none had neurotoxicity. This trial underscores the potential promising treatment of dVHH NS7CAR-Ts in providing clinical benefits with a manageable safety profile to patients with CD7+ AML, warranting further investigation. This trial was registered at www.clinicaltrials.gov as #NCT04938115.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lu P, Zhang X, Yang J, et al. Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia. Blood. 2025. PMID: 39561281. doi:10.1182/blood.2024024861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。